What investment strategy does Lauxera Capital Partners focus on?

Lauxera Capital Partners focuses on Growth strategies in the private equity space.

How many portfolio companies does Lauxera Capital Partners have?

Lauxera Capital Partners has 13 active portfolio companies and 1 completed exit and 2 funds tracked on GP Intel.

Where is Lauxera Capital Partners headquartered?

Lauxera Capital Partners is headquartered in Paris, France.

What is Lauxera Capital Partners's assets under management?

Lauxera Capital Partners manages approximately €660M in assets under management.

When was Lauxera Capital Partners founded?

Lauxera Capital Partners was founded in 2020.

What sectors does Lauxera Capital Partners invest in?

Lauxera Capital Partners invests across Healthcare, Software.

Home/GPs/Lauxera Capital Partners

Lauxera Capital Partners

Paris, France·Founded 2020·

Growth Equity

·lauxera.com

Paris-based healthcare growth-equity firm founded January 2020 specializing in European medtech, biotech and HealthTech scale-ups; deploys EUR 660M across Lauxera Growth I (vintage 2022 EUR 260M) and Lauxera Growth II (vintage 2025 EUR…Read full bio

AUM

€660M

Funds

Portfolio

Exits

SectorsHealthcareSoftware

Key facts

HQParis, France

Founded2020

Websitelauxera.com

Recent exits

OrganOx

Healthcare · 2025

Coverage notes

2 funds tracked, 14 portfolio companies (13 active · 1 realized). Verified weekly from public filings and deal announcements.

About Lauxera Capital Partners

Lauxera Capital Partners is a Paris-based healthcare growth equity firm with €660 million of assets under management as of December 2024, founded in January 2020. The firm specialises in European medtech, biotech and HealthTech scale-ups, deploying capital across Lauxera Growth I (vintage 2022, €260M) and Lauxera Growth II (vintage 2025, €400M) with selective offshore exposure to North American healthcare opportunities.

Investment thesis

Lauxera targets European healthcare growth equity in profitable medtech, biotech and HealthTech scale-ups, with equity tickets typically ranging from €20 million to €60 million per transaction. The growth equity mandate enables Lauxera to back profitable healthcare businesses seeking expansion capital rather than early-stage venture exposure, with the healthcare-exclusive focus providing clinical and regulatory expertise across portfolio companies.

Recent activity

Recent realised exits include OrganOx (healthcare, 2025), reflecting selective distribution activity across the healthcare growth portfolio. The platform tracks 2 funds and 13 active portfolio companies across the healthcare-exclusive programme. Detailed buyer names and multiple data available on Pro at €49/month.